Caption - From Left Mr. S Haresh, Regional Head -Sales & Retail Tamil Nadu & Kerala and Mr. Atul Patel Fund Manager, ICICI Prudential Funds.

NFO OPENS 25TH JUNE 2018 and closeson 9TH JULY 2018

Faceinews Logo - Copy 

Turning India’s improving health opportunities into wealth creation opportunities”


Highlights of the NFO:

ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund is an Open Ended Equity Scheme, which aims to generate long term capital appreciation by investing into the entire spectrum of health-related sub sectors

  • India has one of the largest youth populations. However, with a senior citizen population at ~16Cr, together with increasing life expectancy, demand for healthcare is expected to increase significantly.
  • India has established itself as a global manufacturing and research hub by contributing ~10% of the world production volume, and 50% of its revenue comes from its pharmaceutical exports
  • Currently, at ~5% of GDP, the spending in India is much lower than other developed and developing economies.
  • Valuations are attractive and it’s a good long term opportunity for investments in pharmaceutical  sector


ICICI Prudential MF has announced the launch of ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund. The scheme aims to capitalize on the long-term growth story of Indian healthcare as a whole. Rising income levels, increased health awareness, improvement in treatment technologies and penetration of health insurance has led to healthcare being one of the fastest growing segments in the country. In fact, India has established itself as a global manufacturing and research hub, which contributes around 10% to the world productive volume.


Sharing his views about the fund, Mr. Nimesh Shah, MD & CEO, said, “India continues to remain an under-penetrated market in terms of healthcare services and insurance. As such, non-discretionary spend coupled with increasing awareness make the theme a structural story for long period of time. Due to higher growth, the pharma sector has always traded at a premium relative to the market but the premium has narrowed down significantly in last few years. The recent underperformance of pharma stocks makes a strong case for investing now in this sector.


A renewed focus of the Government on providing healthcare facilities has put the spotlight back on this sector. In fact, the Government initiative, “Pharma Vision 2020” aims to make India a global leader in manufacturing as it enjoys the cost-efficient technology with the production cost around 40% lower than the western countries. The fund seeks to capitalize on all these investment opportunities.

Key Attributes:

§  Plan: Regular and Direct

§  Option: Growth and dividend

§  Minimum application amount: Rs 5,000 and in multiples of one rupee thereafter

§  Benchmark index: S&P BSE Healthcare Index

§  Entry /Exit load: Nil/ upto 18 months: 1%, Nil thereafter

§  Fund manager: Ihab M Dalwai